Standard BioTools' (LAB) shares were down about 9% in recent Thursday trading after KeyBanc downgraded the company's stock to sector weight from overweight.
The downgrade followed the company's "disappointing" full year 2025 guidance, Keybanc said in an earnings recap Wednesday.
The firm said Standard BioTools' 2025 revenue outlook of $165 million to $175 million fell short of the $186.9 million consensus estimate and KeyBanc's $185 million projection.
"The company attributed its guidance to the proposed White House [National Institutes of Health] spending cut that may drive cautious spending for its academic customers," KeyBanc said.
Trading volume stood at more than 3.6 million shares against a daily average of roughly 1.7 million.
Price: 1.07, Change: -0.11, Percent Change: -8.97
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。